MedWatch

Novo upon billion-dollar bid: An acquisition of Ablynx will not satisfy our hunger

Novo Nordisk is currently offering billions in the attempt to acquire the Belgian biotech company Ablynx. And according to Christian Kanstrup, SVP Biopharm operations, the Danish corporation is not planning to cease its acquisitions afterwards.

Foto: Novo Nordisk/PR

During the past month, Novo Nordisk has worked to acquire the Belgian biotech company Ablynx for a sum amounting to more than DKK 20 billion (USD 3.22 billion).

The Danish drug group officially announced its plans of acquiring more companies to support its ailing Biopharm business, including the company’s hemophilia drugs, several quarters ago. And even if Novo Nordisk succeeds in acquiring Ablynx, it is not enough for SVP Christian Kanstrup, who last year was appointed as head of the Biopharm business.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier